Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Coinbase Global, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Coinbase Global, Inc. trades at $160.43 (market cap $43.08B). The key difference: Coinbase Global, Inc. is far larger — about 9.6× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | COIN | |
|---|---|---|
Market Cap | $4.49B | $43.08B |
Sector | Health | Technology |
52-Week High | $28.06 | $419.78 |
52-Week Low | $20.06 | $141.09 |
Enterprise Value | $3.69B | $40.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
COIN trades at $163.51, down 1.19% over 24 hours, with a bearish technical signal and mixed earnings history. The company reported $7.18B revenue in 2025 with a net income margin of 12.2%, though recent quarters showed misses against EPS expectations. Analyst consensus remains bullish with a $233.08 price target, but cash flow trends indicate potential pressure as operating cash flow declined to $2.4B in 2025 from $2.6B in 2024.
The outlook for COIN hinges on execution amid volatile crypto markets, with 55% of analysts rating it a buy. Key risks include regulatory uncertainty and competitive threats, while institutional adoption growth offers upside. Investors should weigh high valuation multiples against earnings volatility and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
